Cn. Sarkissian et al., A different approach to treatment of phenylketonuria: Phenylalanine degradation with recombinant phenylalanine ammonia lyase, P NAS US, 96(5), 1999, pp. 2339-2344
Citations number
40
Categorie Soggetti
Multidisciplinary
Journal title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Phenylketonuria (PKU), with its associated hyperphenylalaninemia (HPA) and
mental retardation, is a classic genetic disease and the first to have an i
dentified chemical cause of impaired cognitive development. Treatment from
birth with a low phenylalanine diet largely prevents the deviant cognitive
phenotype by ameliorating HPA and is recognized as one of the first effecti
ve treatments of a genetic disease. However, compliance with dietary treatm
ent is dif ficult and when it is for life, as now recommended by an interna
tionally used set of guidelines, is probably unrealistic. Herein we describ
e experiments on a mouse model using another modality for treatment of PW c
ompatible with better compliance using ancillary phenylalanine ammonia lyas
e (PAL, EC 4.3.1.5) to degrade phenylalanine, the harmful nutrient in PKU;
in this treatment, PAL acts as a substitute for the enzyme phenylalanine mo
nooxygenase (EC 1.14.16.1), which is deficient in PKU, PAL, a robust enzyme
without need for a cofactor, converts phenylalanine to trans-cinnamic acid
, a harmless metabolite. We describe (i) an efficient recombinant approach
to produce PAL enzyme, (ii) testing of PAL in orthologous N-ethyl-N'-nitros
ourea (ENU) mutant mouse strains with HPA, and (iii) proofs of principle (P
AL reduces HPA)-both pharmacologic (with a clear dose-response effect vs. H
PA after PAL injection) and physiologic (protected enteral PAL is significa
ntly effective vs. HPA). These findings open another way to facilitate trea
tment of this classic genetic disease.